KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.

Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park, Rinath Jeselsohn, Umut Demirci, Miguel Martin, Rachel M Layman, Sara A Hurvitz, Sarah Sammons, Peter A Kaufman, Montserrat Muñoz, Jiun-I Lai, Holly Knoderer, Cynthia Sandoval, Aarti R Chawla, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lacey M Litchfield, Lillian Smyth, Seth A Wander

J Clin Oncol 43(9) 1101-1112

PMID39693591
PMCIDPMC11936477
DOI10.1200/JCO-24-02086
发表日期2024-12-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. METHODS: This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety. RESULTS: This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182 placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2- ABC, offering an additional targeted therapy option for these patients.

KM 提取结果

3 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. Primary analysis of (A) investigator-assessed and (B) BICR-assessed PFS. BICR, blinded independent central review; HR, hazard ratio; NR, not reached; PFS, progression-free survival.

A

investigator-assessed PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

BICR-assessed PFS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIG A1.

FIG A1. Interim analysis of investigator-assessed PFS. HR, hazard ratio; PFS, progression-free survival.

PFS

progression-free survival

FIG A1. · Panel PFS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel PFS 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure8 个面板

FIG A2.

FIG A2. Investigator-assessed PFS for clinically relevant subgroups: (A) patients with visceral metastasis; (B) patients without visceral metastasis; (C) patients with liver metastasis; (D) patients without liver metastasis; (E) patients with bone-only disease; (F) patients without bone-only disease; (G) patients who received previous CDK4/6i for < 12 months; and (H) patients who received previous CDK4/6i for ≥12 months. CDK4/6i, cyclin-dependent kinase 4/6 inhibitor(s); HR, hazard ratio; NR, not reached; PFS, progression-free survival.

A

PFS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG A2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

PFS

FIG A2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

PFS

FIG A2. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

PFS

FIG A2. · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

PFS

FIG A2. · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
G

PFS

FIG A2. · Panel G

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel G 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
H

PFS

FIG A2. · Panel H

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel H 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. a Includes four deaths due to AE and one death due to study disease. b Death due to study disease. AE, adverse event.
非 KM Figure
FIG 3.FIG 3. (A) Investigator-assessed and (B) BICR-assessed PFS in clinically relevant subgroups. ABC, advanced breast cancer; BICR, blinded independent central review; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor(s); HR, hazard ratio; PFS, progression-free survival; PR, progesterone receptor.
非 KM Figure
FIG 4.FIG 4. Exploratory biomarker analysis in biomarker-evaluable population. (A) Frequency of gene alterations in ESR1 and the PI3K pathway. (B) Investigator-assessed PFS. ctDNA, circulating tumor DNA; HR, hazard ratio; PFS, progression-free survival.
非 KM Figure